71
Participants
Start Date
March 26, 2020
Primary Completion Date
December 7, 2023
Study Completion Date
October 31, 2024
Zanidatamab
Administered intravenously
Docetaxel
Administered intravenously
Tislelizumab
Administered intravenously
Capecitabine
Administered orally
Oxaliplatin
Administered intravenously
National Cheng Kung University Hospital, Tainan City
National Cancer Center, Goyang-si
Taipei Veterans General Hospital, Taipei
Seoul National University Bundang Hospital, Seongnam-si
China Medical University Hospital, Taichung
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
The Affiliated Hospital of Military Medical Sciences, Beijing
Beijing Cancer Hospital, Beijing
National Taiwan University Hospital East Campus, Taipei
Liaoning Cancer Hospital and Institute, Shenyang
Jilin Cancer Hospital, Changchun
Zhejiang Cancer Hospital, Hangzhou
The Third Hospital of Nanchang, Nanchang
Chongqing Cancer Hospital, Chongqing
Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Gangnam Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Korea University Guro Hospital, Seoul
Lead Sponsor
BeiGene
INDUSTRY